Table 2 Prognostic implication of PCT as a continuous variable on AKI development and 30-day mortality in critically ill patients.

From: Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients

 

Crude

Model 1

Model 2

Model 3

Model 4

OR (95% CI), P

OR (95% CI), P

OR (95% CI), P

OR (95% CI), P

OR (95% CI), P

AKI (N = 266)

1.007 (1.003–1.011) 0.002

1.007 (1.002–1.011), 0.003

1.008 (1.003–1.012), 0.001

1.006 (1.002–1.011), 0.007

1.006 (1.000–1.011), 0.035

30-day mortality (N = 99)

0.997 (0.990–1.004) 0.373

0.996 (0.989–1.003) 0.301

0.997 (0.989–1.004), 0.350

0.996 (0.989–1.003), 0.265

0.999 (0.991–1.007), 0.798

  1. Model 1: adjusted for demographics (age >65, female sex).
  2. Model 2: adjusted for demographics, and comorbidities (model 1 + CKD, DM, HTN, CVD, CLD, COPD, and asthma).
  3. Model 3: adjusted for demographics, comorbidities, and AKI risk factors (model 2 + RAS blockers, inotropes, transfusion, ventilator, aminoglycosides, vancomycin, colistin, amphotericin, NSAID, contrast media, and chemotherapy).
  4. Model 4: adjusted for demographics, comorbidities, AKI risk factors, and laboratory findings (model 3 + Hb, hsCRP, albumin, WBC, and SOFA score).
  5. Abbreviations: OR, odds ratio; PCT, procalcitonin; AKI, acute kidney injury; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; RAS, renin-angiotensin-aldosterone system; CCB, calcium channel blocker; NSAID, nonsteroidal anti-inflammatory drug; hsCRP, highly sensitive C-reactive protein; WBC, white blood cell; SOFA, Sequential Organ Failure Assessment.
Back to article page